ORDER A TEST Log In Contact Us
Hero Background

PROVIDERS /// ONCOLOGY

Creating more options for your patients

Our collection of offerings uncover unique insights that empower you to customize treatment for individual patients, throughout their cancer journey.

CONTACT us

A comprehensive solution for all of your precision oncology needs

  1. GENOMIC PROFILING

    We deliver a comprehensive view of your patients through our tissue and liquid tests, DNA and RNA sequencing, somatic and germline tests, tumor-normal matched profiling, and MRD and monitoring test options.
  2. ALGORITHMIC TESTS

    We leverage our growing database to create specialized algorithms like Homologous Recombination Deficiency (HRD), Tumor Origin (TO), and DPYD, with more algorithms in development.
  3. TEMPUS HUB

    We offer a fast, reliable platform for ordering Tempus tests, accessing patient insights, and utilizing our AI-driven technologies seamlessly.

  4. TEMPUS ONE

    The first generative AI-enabled clinical assistant that provides access to patient insights directly at your fingertips.
  5. EHR INTEGRATION

    We offer easy access to current treatment options and relevant insights through our integration and connectivity capabilities.
  6. TEMPUS+

    We provide select participating institutions with access to technical support, customized to meet the unique needs and goals of your cancer center.
  7. CLINICAL TRIAL MATCHING

    We bring just-in-time clinical trial options to patients based on clinical and molecular data, for enrollment at your institution, through our TIME Trial Program—in days instead of months.
  8. DIGITAL PATHOLOGY

    We are developing AI capabilities to help pathologists find actionable markers in specimens to identify potential patients for clinical trials or precision therapeutics.
  9. CARE PATHWAY SOLUTIONS

    We empower physicians to deliver the next step in a patient’s care journey with our AI-enabled care pathway intelligence platform.

Streamlining your workflow

One order. One platform. One financial assistance program.

Browse our FAQs
Financial Assistance

Tempus is committed to providing easy and affordable access to our tests and services.

  • Apply for financial assistance online at access.tempus.com.

  • If approved, you will know immediately about the maximum out of pocket cost of your testing.

  • Please contact billing@tempus.com if you are concerned about out-of-pocket costs and would like to discuss your options.

All U.S.-based patients are eligible to apply for financial assistance regardless of insurance status. For uninsured and international patients, we offer a self-pay option. If you have any questions, please email patients@tempus.com.

Authorization for Medical Records: Through access.tempus.com, you will be directed to our Notice and Authorization for Medical Records authorization form. This optional form allows us to request outcomes and other medical records from your health care providers. Please see the form for more information.

We have established relationships that span from community practices to more than 50% of all academic medical centers in the United States.

Open video in popup image description
Open video in popup image description
Working with the top hospitals in North America

In the rapidly changing world of cancer care and precision medicine, Tempus is the established leader. They provide rapid, accurate results while also continuing to develop innovative strategies to improve patient outcomes. With a focus on both clearly defining actionable mutations and extending treatment options by matching specific patients to specific local and national studies, Tempus is directly changing the patients' lives.

Joseph K Hofmeister, MD, OhioHealth

Working with the top hospitals in North America

Breast cancer care has involved use of biomarkers for years in order to determine appropriate therapy. Genomic information has now been added to the list of crucial biomarkers needed to know how to treat metastatic breast cancer patients with the approval of targeted therapy for BRCA and PIK3CA mutations. Having this information also gives a patient the best opportunity to consider one of numerous biomarker driven clinical trials. These options allow as personalized an approach to treatment as possible and I have no doubt that genomic data will continue to transform the way patients are treated as our field moves forward.

Megan Kruse, MD, Cleveland Clinic

  • 6.5K+

    oncologists rely on Tempus as their precision medicine partner

  • 30K+

    patients have been identified for potential enrollment into clinical trials in our network

  • 8M+

    de-identified research records

  • 40+

    operational countries across North, Central and South America, Europe, the Middle East, and Asia

image description

Our Science

view all publications
  • UPCOMING WEBINAR:

    Real-World Outcomes of ALK Fusion Types and Treatment Patterns in ALK-Positive NSCLC: Insights from a Retrospective Cohort Study

    In this retrospective cohort study, a diversity of ALK fusion events were demonstrated with potential impacts on treatment outcomes

    Read more
  • UPCOMING WEBINAR:

    Impact of PSA Nadir on Long-Term Survival in Metastatic Hormone-Sensitive Prostate Cancer: Final 10-Year Analysis of the ECOG-ACRIN E3805 CHAARTED Trial

    In this post hoc OS analysis of the CHAARTED trial (NCT00309985), we report 10-year OS and cause of death (COD) by baseline clinical factors, PSA nadir at 6 months in mHSPC patients treated with ADT +/- D.

    Read more
  • UPCOMING WEBINAR:

    Acquired RUFY1-RET Rearrangement as a Mechanism of Resistance to Lorlatinib in a Patient With CD74-ROS1 Rearranged Non-Small Cell Lung Cancer: A Case Report

    Here we present a case of a patient with stage IV CD-74-ROS1 fusion NSCLC discovered initially with RNA next generation sequencing (NGS) who acquired resistance to lorlatinib after 6 months on therapy through a novel RUFY1-RET fusion, detected only through RNA NGS.

    Read more
  • UPCOMING WEBINAR:

    Correlation of Mesothelin (MSLN) Expression Measured by RNA Sequencing (RNASeq) and Immunohistochemistry (IHC) in MSLN-Expressing Tumors

    The aim of this analysis was to determine whether MSLN expression measured by RNAseq and IHC are correlated among patients with solid tumors.

    Read more
  • UPCOMING WEBINAR:

    Real-World Clinical Multi-Omics Analyses Reveal Bifurcation of ER-Independent and ER-Dependent Drug Resistance to CDK4/6 Inhibitors

    To better understand drug resistance mechanisms to CDK4/6 inhibitors and inform precision medicine, we analyze real-world multi-omics data from 400 HR+/HER2- metastatic breast cancer patients treated with CDK4/6 inhibitors plus endocrine therapies, including 200 pre-treatment and 227 post-progression samples.

    Read more
  • UPCOMING WEBINAR:

    Molecular Differences in Pancreatic Ductal Adenocarcinomas from Black versus White Patients

    These findings suggest race-associated molecular differences in tumors that may impact patient responses to immunotherapies. Our study also supports the importance of improving patient diversity in clinical trials on pancreatic cancer treatments.

    Read more

Featured News and Events

view all news
  • UPCOMING WEBINAR:

    Tempus and Stemline Therapeutics, Inc., A Subsidiary of the Menarini Group, Announce Collaboration to Implement Tempus Next, an AI-Enabled Care Pathway Intelligence Platform to Support Patients with Metastatic Breast Cancer

    Tempus, the Menarini Group (“Menarini”), and Stemline Therapeutics, Inc. (“Stemline”), announced a new collaboration. The two companies will leverage Next – Tempus’ AI-enabled care pathway intelligence platform – to help clinicians determine when an ESR1 test may be appropriate.

    Read more
  • UPCOMING WEBINAR:

    Tempus Announces Collaboration with IFLI Aimed at Supporting Development of Targeted Therapies for Follicular Lymphoma

    Tempus announced a new collaboration with the Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL).

    Read more
  • UPCOMING WEBINAR:

    Tempus Completes Acquisition of Ambry Genetics

    Tempus announced it has completed its acquisition of Ambry Genetics, a recognized leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease.

    Read more
  • UPCOMING WEBINAR:

    Tempus Launches Beta Version of olivia, its AI-enabled Personal Health Concierge App for Patients

    Tempus announced the beta launch of a patient-facing app, olivia, an AI-enabled personal health concierge to empower individuals to holistically organize, manage, and proactively take control of their own health data.

    Read more
  • UPCOMING WEBINAR:

    Tempus Announces the National Launch of FDA-Approved xT CDx Test

    Tempus announced the national launch of the company’s FDA-approved, NGS-based in vitro diagnostic device, xT CDx. Beginning today, xT CDx is now available for all ordering clinicians nationwide.

    Read more
  • UPCOMING WEBINAR:

    Tempus One Introduces New GenAI Capabilities to Query Millions of Unstructured Documents for Research and Clinical Care

    Tempus introduced a suite of new, transformative capabilities available in Tempus One, the company’s generative AI assistant, which now applies Tempus’ proprietary Large Language Model (LLM) Agent Infrastructure (Agent Builder), which adapts LLMs to work on unstructured, multimodal healthcare data to improve clinical care and research.

    Read more

Validations and Resources

view all resources
  • UPCOMING WEBINAR:

    Tempus xT Validation

    Our Tempus xT assay is designed to detect actionable oncologic targets by sequencing tumor samples with matched normal saliva or blood samples, when available.

    Read more
  • UPCOMING WEBINAR:

    Tempus xF Validation

    Our non-invasive Tempus xF liquid biopsy assay detects cell-free DNA (cfDNA) in blood specimens of advanced solid tumor patients.

    Read more
  • UPCOMING WEBINAR:

    Standard Requisition Form

    We offer an easy ordering process which allows you to order any of somatic and germline panels along with our add-on tests like HRD, TO and DPYD.

    View here

Partnering with Tempus is investing in the future

Every new test and data point strengthens our algorithms, predictions, and recommendations to improve treatment options for future patients.